Literature DB >> 18559719

Aldosterone, hypertension, and cardiovascular disease: an endless story.

Luís M Ruilope.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18559719     DOI： 10.1161/HYPERTENSIONAHA.108.111211

Source DB:  PubMed          Journal:  Hypertension        ISSN： 0194-911X            Impact factor:   10.190


× No keyword cloud information.
  5 in total

Review 1.  Management of primary aldosteronism and mineralocorticoid receptor-associated hypertension.

Authors:  Satoshi Morimoto; Atsuhiro Ichihara
Journal:  Hypertens Res       Date:  2020-05-18       Impact factor: 3.872

Review 2.  Newer Drugs to Reduce High Blood Pressure and Mitigate Hypertensive Target Organ Damage.

Authors:  Bharathi Upadhya; Patrick M Kozak; Richard Brandon Stacey; Ramachandran S Vasan
Journal:  Curr Hypertens Rep       Date:  2022-02-14       Impact factor: 5.369

Review 3.  Interventional procedures and future drug therapy for hypertension.

Authors:  Melvin D Lobo; Paul A Sobotka; Atul Pathak
Journal:  Eur Heart J       Date:  2017-04-14       Impact factor: 29.983

Review 4.  Managing resistant hypertension: focus on mineralocorticoid-receptor antagonists.

Authors:  Juan Carlos Yugar-Toledo; Rodrigo Modolo; Ana Paula de Faria; Heitor Moreno
Journal:  Vasc Health Risk Manag       Date:  2017-10-16

Review 5.  Aldosterone synthase inhibitors in hypertension: current status and future possibilities.

Authors:  Milan Hargovan; Albert Ferro
Journal:  JRSM Cardiovasc Dis       Date:  2014-02-05
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.